Clinical data
Legal status
Identifiers
4-fluoro-N-(2-{4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide
PubChem CID
Chemical and physical data
C22H26FN3O4
415.465 g·mol−1
3D model (JSmol)
C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO
InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1
Key:NYSDRDDQELAVKP-SFHVURJKSA-N
Flesinoxan (DU-29,373) is a potent and selective 5-HT1A receptor partial/near-full agonist of the phenylpiperazine class.[1][2][3] Originally developed as a potential antihypertensive drug,[1][2][4] flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests.[5][6] As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability.[7][8] However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.[9]
In patients, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion.[2][8]
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
TeCAsTooltip Tetracyclic antidepressants
Others
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Others
Simple piperazines
(no additional rings)
Diphenylalkylpiperazines
(benzhydrylalkylpiperazines)
Tricyclics
(piperazine attached via side chain)
Others/Uncategorized